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• This comprehensive comparison of the genetic subtypes of hemochromatosis reveals 
more severe iron overload and disease in non-HFE forms 
• Arthropathy is more common in HFE-related hemochromatosis suggesting that joint 
disease may not be associated with iron 
 




The clinical progression of HFE-related hereditary hemochromatosis (HH) and its phenotypic 
variability has been well studied. Less is known about the natural history of non-HFE HH 
caused by mutations in the HJV, HAMP or TFR2 genes. The purpose of this study was to 
compare the phenotypic and clinical presentations of hepcidin-deficient forms of HH. A 
literature review of all published cases of genetically confirmed HJV, HAMP and TFR2 HH 
was performed. Phenotypic and clinical data from a total of 156 subjects with non-HFE HH 
was extracted from 53 publications and compared with data from 984 subjects with HFE-
p.C282Y homozygous HH from the QIMR Berghofer Hemochromatosis Database. Analyses 
confirmed that non-HFE forms of HH have an earlier age of onset and a more severe clinical 
course than HFE HH. HJV and HAMP HH are phenotypically and clinically very similar and 
have the most severe presentation, with cardiomyopathy and hypogonadism being 
particularly prevalent findings. TFR2 HH is more intermediate in its age of onset and severity. 
All clinical outcomes analyzed were more prevalent in the juvenile forms of HH, with the 
exception of arthritis and arthropathy which were more commonly seen in HFE HH. This is the 
first comprehensive analysis comparing the different phenotypic and clinical aspects of the 
genetic forms of HH and the results will be valuable for the differential diagnosis and 
management of these conditions. Importantly, our analyses indicate that factors other than 
iron overload may be contributing to joint pathology in subjects with HFE HH. 




Hereditary hemochromatosis (HH), is a potentially debilitating genetic disease of systemic 
iron overload, caused by mutations in genes involved in the regulation of iron homeostasis.1 
These mutations lead to increased absorption of iron, resulting in excessive iron deposition in 
tissues with eventual organ damage and disease. HH results in a clinical spectrum of disease 
with the potential for cardiac involvement (including cardiomyopathy), hypogonadism, 
diabetes, skin pigmentation, arthritis and liver fibrosis.2 Fortunately, early clinical suspicion, 
pathology testing, diagnosis and subsequent treatment reverses tissue iron deposition and 
prevents progression of most of the pathology associated with the disease. 
The most common form of HH is caused by homozygosity for the HFE p.C282Y mutation 
(HFE HH).3,4 Rarely, HFE HH can be caused by other mutations in the HFE gene including 
compound heterozygosity for p.C282Y and the more common but less penetrant p.H63D 
mutation.5,6 Non-HFE forms of HH (non-HFE HH) are caused by mutations in genes involved 
in iron homeostasis other than HFE. These forms of non-HFE HH are more genetically 
heterogeneous, with varying patterns of clinical expression.7,8 Similar to HFE HH, these less 
common genetic conditions can be caused by defects that affect the hepcidin-ferroportin axis, 
including homozygosity or compound heterozygosity for pathogenic mutations in the genes 
encoding hemojuvelin (HJV),9 hepcidin (HAMP),10 transferrin receptor 2 (TFR2),11 or 
heterozygosity for pathogenic mutations in the ferroportin gene (SLC40A1).12,13 HFE HH is 
predominantly responsible for iron overload cases in populations of European descent. It is of 
note that non-HFE HH appears to affect both European and non-European populations,14 with 
case reports from various geographical locations and ethnic groups. While some forms of 
non-HFE HH are more severe than HFE HH, they have thus far only been documented in 
case reports, small case studies15 and a single meta-analysis of Ferroportin disease.16 No 
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large scale formal analysis has thus far been performed to compare the phenotypic and 
clinical features of non-HFE forms of HH.  
In the autosomal recessive forms of HH caused by mutations in either HFE, HJV, HAMP or 
TFR2, hepcidin production by the liver is inadequate to downregulate expression of cell-
surface ferroportin, leading to enhanced iron absorption and recycling.1 Hence these forms of 
HH have a similar underlying pathophysiology, with phenotypic differences most likely due to 
the degree of impairment in the pathways controlling hepatic hepcidin production. In contrast, 
mutations in ferroportin can lead to different phenotypic presentations of iron overload 
depending on whether the mutation affects the iron transport ability of ferroportin or its 
sensitivity to hepcidin-mediated downregulation.7 
The aims of this study were to compare the phenotypic and clinical disease features of 
patients with HFE versus those with hepcidin deficient non-HFE forms of HH to gain a better 
understanding of the natural history of these iron-associated disorders and aid in their 
differential diagnosis. This may ultimately provide clinicians and patients with better guidance 
in the diagnosis, prognostication and management of iron overload disease both before and 
after genetic testing. Our analysis has produced the first guide of clinical features matched to 
serological markers and HH gene mutations, and forms a valuable resource for informing the 
medical and research community on the clinical comparison of these iron overload disorders. 





This study was approved by the QIMR Berghofer Human Research Ethics Committee and 
performed in accordance with the Declaration of Helsinki (1975). For patients derived from the 
QIMR Berghofer Hemochromatosis Database, informed and written consent was obtained for 
these studies. Institutional approvals for all other patients were provided in the original 
publications from which they were derived. 
 
Creation of non-HFE HH database 
We conducted a systematic literature review using PubMed to identify all published cases of 
genetically confirmed autosomal recessive non-HFE HH caused by mutations in HJV, HAMP 
and TFR2, up until March 2016, as previously described.17 HH due to mutations in SLC40A1 
or other genes involved in iron homeostasis outside of the hepcidin-ferroportin axis were not 
included in this study due to underlying differences in pathophysiology. From the available 
journal articles, data regarding the genetic, phenotypic, demographic and clinical outcomes of 
individual patients was manually extracted and compiled into a database. The extracted data 
was cross-checked and the validity of the data was verified by a second investigator. Subjects 
were included if they were homozygous or compound heterozygous for HH-related mutations 
in either the HJV, HAMP or TFR2 genes. In addition, data from HFE-p.C282Y homozygous 
individuals from the QIMR Berghofer Hemochromatosis Database was used as a comparison 
group in the analyses. The following parameters were included in the analyses: genetic cause 
of HH, sex, age at diagnosis, serum ferritin (SF), transferrin saturation (TS), and the presence 
of 6 clinical outcomes: (a) cardiac involvement (including cardiomyopathy), (b) hypogonadism, 
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(c) diabetes or abnormalities in blood glucose, (d) skin pigmentation, (e) arthritis or 
arthropathy, and (f) liver fibrosis or cirrhosis. Publications that did not include the key data of 
genotype, sex, age at diagnosis, serum ferritin or transferrin saturation of individual patients 
were not included in the analyses.  
 
Statistical Analyses 
Patient data was analyzed using Graphpad Prism version 6 or SPSS version 15.0 with the 
assistance of an experienced statistician (MDC). Continuous variables were compared 
between groups using 1-way-ANOVA with Tukey’s multiple comparison test or Kruskal-Wallis 
with Dunn’s multiple comparison test. Categorical variables were compared between groups 
using Fisher’s exact test. Logistic regression models were fit to examine how the genetic 
cause of HH is associated with a clinical feature (a) not adjusting for any variables, (b) 
adjusting for age group (<25y, 25-34y, 35-44y, 45-54y, 55y+) and sex, (c) adjusting for log SF 
(linear relation with log odds assumed) and (d) adjusting for age group, sex and log SF. 





A total of 156 subjects with genetically confirmed autosomal recessive non-HFE HH, with 
phenotypic and clinical data available, were identified from a total of 53 publications (Table 1). 
This included 99 HJV (Type 2A HH), 11 HAMP (Type 2B HH), and 46 TFR2 (Type 3 HH) 
subjects. The genotypes associated with these subjects and publications from which they 
were derived are shown in Table 1. From the QIMR Berghofer Hemochromatosis Database a 
total of 984 subjects with HFE HH due to p.C282Y homozygosity were identified for 
comparison. These HFE HH subjects were further subdivided into 558 probands and 426 
non-probands (relatives of probands identified through family screening). 
 
Gender Distribution 
The gender distribution of subjects with non-HFE and HFE HH were compared (Supplemental 
Table S1). There were similar proportions of males and females in the HJV HH group that did 
not deviate significantly from the expected ratio of 1:1. There were more males than females 
in the HAMP and TFR2 groups, however, the ratios did not statistically deviate from the 
expected 1:1 ratio, possibly because of the low number of subjects in these groups. There 
were significantly more males than females in the HFE proband group (64% versus 35%; 
binomial test, p<0.0001). As expected the HFE non-proband group, which were identified 
through family screening, had equal numbers of males and females. These results are 
consistent with the more severe clinical course seen in males compared to females with HFE 
HH and the more equal gender distribution that has been observed in subjects with juvenile 
forms of HH.18 
For personal use only.on June 10, 2018. by guest  www.bloodjournal.orgFrom 
9 
 
Age at Diagnosis 
The age at diagnosis was lower for all forms of non-HFE HH studied when compared to HFE 
HH (Figure 1 and Supplemental Table S1). Mean age at diagnosis was similar for HJV HH 
and HAMP HH (24 and 26 years respectively). Mean age at diagnosis for TFR2 HH (32 
years) was significantly higher than for HJV HH, whilst being intermediate between the 
juvenile forms of HH and HFE HH (HFE probands: 45 years; HFE non-probands: 40 years). 
The spread of age at diagnosis was quite large for all forms of HH (Figure 1), suggesting that 
there is a high level of phenotypic variability among all forms of HH regardless of the genetic 
cause. 
 
Serum Iron Indices 
SF concentration and TS were measured in the majority of subjects at diagnosis (Figure 2 
and Supplemental Table S1). SF levels, a surrogate marker of storage iron, were greatly 
elevated in all of the non-HFE HH groups (Figure 2A and Supplemental Table S1) with similar 
levels in the HJV and HAMP HH groups (median SF 2925 and 3050 µg/L respectively). SF 
was significantly lower in TFR2 HH (median SF 1800 µg/L) compared to HJV HH, with a 
broader spread of values. SF levels were lowest in the HFE HH subjects with the HFE non-
probands (median SF 463 µg/L) having significantly lower levels compared with the HFE 
probands (median SF 937 µg/L). 
Similar to SF, TS, a measure of transport iron, was greatly elevated in all non-HFE HH 
groups, with a median TS of 96% in all three groups (Figure 2B and Supplemental Table S1). 
All but one of the non-HFE HH subjects had TS above 59%, a value well above the normal 
reference range and indicative of HH. This subject with TFR2 HH also had the lowest SF and 
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was a 43 year old female with iron deficiency without anemia, that had been attributed to a 
history of low dietary iron consumption and blood loss.19 TS was significantly lower in the HFE 
HH groups and the spread of values was much greater (Figure 2B). The TS was significantly 
lower in HFE non-probands (median TS 70%) compared to the HFE probands (median TS 
84%). 
We also analyzed the relationship between serum iron indices and age at diagnosis by 
plotting age against either SF or TS at diagnosis (Supplemental Figure S1). As can be seen in 
Supplemental Figure S1A, there is a wide range of values for age and SF at diagnosis for 
subjects with HH. However, those with HJV or HAMP HH and to a lesser extent TFR2 HH, 
cluster towards the upper left of the plot, reflecting the earlier onset and more severe iron 
loading seen in these forms of HH. A similar observation can be made for age versus TS at 
diagnosis (Supplemental Figure S1B). 
 
Clinical Disease Features at Presentation 
We accounted for the following clinical features in this study: cardiac involvement, 
hypogonadism, diabetes or hyperglycemia, skin pigmentation, arthritis or arthropathy, and 
liver fibrosis or cirrhosis (Figure 3 and Supplemental Table S1). Cardiac involvement and 
hypogonadism were more prevalent in the non-HFE HH groups when compared to HFE HH 
(Fisher’s exact test: p<0.0001 and p<0.0001 respectively). Hypogonadism was also more 
prevalent in the HJV and HAMP HH groups compared to the TFR2 HH group (75% versus 
50%, Fisher’s exact test: p=0.023). Cardiac involvement was more prevalent in the HJV and 
HAMP HH groups compared to the TFR2 HH group (41% versus 23%), however, this did not 
reach statistical significance, possibly due to the absence of some data in the TFR2 group. 
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These results confirm cardiomyopathy and hypogonadism as hallmark features of the juvenile 
form of HH.15 Other clinical outcomes such as diabetes/hyperglycemia, skin pigmentation and 
liver fibrosis were also more prevalent in the non-HFE compared to HFE groups, however, 
these only reached statistical significance consistently for the HJV HH group. 
The one exception to the increased prevalence of clinical disease features in non-HFE HH 
compared to HFE HH was arthritis/arthropathy, a clinical feature that was most prevalent in 
HFE probands, with statistically lower prevalence in the HJV group (Figure 3). The prevalence 




To better understand the relationship between genetics, gender, age, iron indices and clinical 
disease features, we performed logistic regression analyses using four different models. 
These analyses examined how the genetic form of HH is associated with a clinical feature, 
and in the case of HFE HH whether being a proband or non-proband influences the clinical 
presentation. For these analyses we combined the juvenile HH groups, HJV and HAMP, 
which represents all patients with the classical juvenile form of HH, due principally to the small 
size of the HAMP group (n=11) and also because the demographic, phenotypic and clinical 
features between these two groups were so similar. 
The odds ratio (OR) for each of the six clinical features are shown for the HJV/HAMP, TFR2 
and HFE non-proband groups in comparison to the HFE proband group (Table 2). Regression 
analysis was performed on clinical features from all subjects excluding those with missing 
data on some of these clinical features (Table 2 and Supplemental Table S2) or including 
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these subjects in the analysis (Supplemental Table S3). Similar results were obtained using 
both approaches. The first regression model did not adjust for any variables (Model 1) and 
showed a statistically significant increase in the OR for the HJV/HAMP group (vs. HFE 
probands) for all six clinical features (Table 2), with the OR for cardiac involvement (OR=11.6) 
and hypogonadism (OR=12) being highest (p<0.001). The ORs for diabetes/hyperglycaemia 
(OR=3.8), skin pigmentation (OR=6) and liver fibrosis (OR=3.4) were also statistically 
elevated (p<0.001) in the HJV/HAMP group but the magnitude of change was lower in 
comparison to cardiac involvement and hypogonadism. The OR for cardiac involvement 
(OR=4.9), hypogonadism (OR=3.9) and liver fibrosis/cirrhosis (OR=3.1) were statistically 
higher in the TFR2 group (vs. HFE probands) but there were no statistically significant 
changes in this group for diabetes/hyperglycemia, skin pigmentation or arthritis/arthropathy. 
Three additional regression models were performed adjusting for age group, sex and log SF 
(Model 2 – Table 2 and Supplemental Table S3), age group and sex alone (Model 3 – 
Supplemental Table S2 and S3) and log SF alone (Model 4 – Supplemental Table S2 and 
S3). After adjusting for age group, sex and log SF (Model 2 – Table 2), significant 
associations were still seen in the HJV/HAMP group for cardiac involvement (OR=31.3), 
hypogonadism (OR=19.4), diabetes/hyperglycemia (OR=8.4), and skin pigmentation 
(OR=12.4) when compared to HFE probands. After adjusting for age group, sex and log SF, 
significant associations were observed in the TFR2 group for cardiac involvement (OR=7.1), 
hypogonadism (OR=5.2) and diabetes/hyperglycaemia (OR=3.8). 
After adjusting for age group and sex alone the ORs for cardiac involvement, hypogonadism, 
diabetes/hyperglycemia, skin pigmentation and liver fibrosis increased in the HJV/HAMP 
group with more significant associations (Model 3 – Supplemental Table S2). The same was 
the case for the TFR2 group, although the effect sizes were smaller. Adjusting for log SF 
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decreased the ORs for these five clinical features in the HJV/HAMP group, although 
significant associations were still seen for cardiac involvement, hypogonadism, 
diabetes/hyperglycaemia and skin pigmentation (Model 4 – Supplemental Table S2). The 
ORs for cardiac involvement and hypogonadism also remained significant in the TFR2 group 
after adjusting for log SF (Model 4 – Supplemental Table S2). 
In contrast to the other clinical features, the OR for arthritis/arthropathy was significantly lower 
in the HJV/HAMP group (OR=0.47) consistent with the lower incidence in this group 
compared to HFE probands (Model 1, Table 2). When adjusted for age group, sex and log SF 
(Model 2, Table 2) or age group alone (Model 3, Supplemental Table S2) the association 
disappeared (OR=1.2 and 1.7 respectively), suggesting that the lower incidence of 
arthritis/arthropathy in HJV/HAMP may be due to the younger age at diagnosis. When 
adjusted for log SF alone (Model 4, Supplemental Table S2) the association was stronger 
(OR=0.35), suggesting that arthritis in HH may not be solely due, or directly related, to iron 
load. 
When comparing the HFE non-proband group with HFE probands the ORs for all six clinical 
features were significantly lower. After adjusting for age group, sex and log SF, these 
associations disappeared for cardiac involvement, hypogonadism and skin pigmentation. 
However, ORs were still significantly lower for diabetes/hyperglycemia, liver fibrosis and to a 
lesser extent arthritis/arthopathy after adjusting for these variables. 
 




This study is the first comprehensive phenotypic and clinical analysis of subjects with 
hepcidin-deficient forms of HH caused by both HFE and non-HFE genes. The four types of 
HH analyzed (HFE, HJV, HAMP and TFR2) all result from deficiency of functional hepcidin, 
the iron-regulatory hormone, with differing phenotypic severities, based on the degree of 
hepcidin dysregulation. This study analyzed a total of 156 subjects with non-HFE HH with a 
wide variety of genotypes. The 70 different genotypes present across the HJV, HAMP and 
TFR2 genes (Table 1) meant that it was difficult to perform any meaningful genotype-
phenotype correlations. It is of note that the majority of subjects with non-HFE HH (81%) were 
homozygous for mutations, with the remainder being compound heterozygous. This suggests 
a high degree of consanguinity among non-HFE HH families or that families came from 
isolated populations, an aspect of non-HFE HH genetics that has been alluded to in several 
published studies.20,21 While, the subjects with non-HFE HH in this study were derived from 
global populations, it is of note that there was a high proportion from Europe and in particular 
Italy (30%) and Greece (10%). Whether this reflects the true distribution of non-HFE forms of 
HH or that these forms of HH are recognised, diagnosed and researched more in these areas 
is unclear. 
Our analyses confirm that subjects with non-HFE HH have an earlier age at diagnosis and 
more severe iron loading than subjects with HFE HH. The two subtypes, HJV and HAMP HH, 
are appropriately classified as “juvenile hemochromatosis”, having an earlier age of onset and 
the most severe iron loading and clinical course. Clinical presentation for hypogonadism and 
cardiomyopathy are particularly prevalent in HJV and HAMP HH. TFR2 HH is more 
intermediate in its onset and severity relative to both the juvenile forms of HH and to HFE HH. 
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Most clinical features, including cardiac involvement, hypogonadism, diabetes, skin 
pigmentation and liver fibrosis, were more prevalent in subjects with non-HFE HH compared 
to HFE HH. Cardiomyopathy and hypogonadism are particularly prevalent clinical findings in 
HJV and HAMP HH and are strongly associated with these types of HH even after adjusting 
for age at diagnosis, sex and SF. The data suggests that in juvenile forms of HH the earlier 
and more rapid accumulation of iron has a much more profound effect on the heart and 
endocrine system resulting in the higher incidence of cardiomyopathy and hypogonadism 
seen in patients with HJV or HAMP related HH. These results may indicate an increased 
susceptibility of cardiac tissue and the pituitary to the damaging effects of iron during 
development. It may also indicate a much earlier deposition of iron in the heart and pituitary in 
juvenile HH when compared to HFE HH, where iron deposition in these tissues either occurs 
much later or not at all. In other organ systems such as the liver, pancreas and skin, although 
the effects of iron accumulation can be seen at an earlier age in non-HFE HH, multivariate 
analyses indicate that the pathology can be mostly attributed to the amount of iron that has 
accumulated. Previous studies in mouse models of HH indicate that the liver accumulates iron 
early in all forms of HH but plateaus at different levels depending on the genetic cause.22 Iron 
then starts to accumulate more rapidly in the pancreas followed by the heart in juvenile forms 
of HH. This may be explained as a threshold effect where once the liver is iron-loaded to a 
certain level, iron then accumulates in other organs including the pancreas, heart and 
pituitary, although this remains to be proven. This threshold level in the juvenile forms of HH 
is likely to be attained at a younger age resulting in the earlier and more damaging effects of 
iron deposition in the heart and pituitary. In HFE HH this threshold level may be reached 
much later in life or may never be achieved in subjects with milder phenotypes, leading to the 
much lower prevalence of cardiomyopathy and hypogonadism in this type of HH. 
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The relatively high prevalence of arthritis and arthropathy in HFE HH compared to the non-
HFE forms of HH is unusual. While age at diagnosis may partly explain why joint pathologies 
are more common in HFE HH, adjusting for iron loading as reflected by log SF increases the 
association of arthritis/arthropathy with HFE HH. This suggests that factors other than body 
iron stores may be contributing to joint disease in HFE HH. This idea is supported by 
evidence that venesection treatment does not always relieve joint symptoms in HH patients 
and that arthritis can often progress even after iron levels have been normalized.23,24 This is in 
contrast to other HH-associated pathologies that are normally reversed after venesection 
treatment.23 There are several possibilities that could explain the higher prevalence of arthritis 
in HFE HH: HFE may have alternate functions unrelated to systemic iron regulation in joint 
tissue or iron may be distributed differently so that it has more damaging effects in the joints 
of HFE compared to non-HFE subjects. Studies that have followed non-HFE subjects post 
diagnosis and treatment are lacking, so whether they develop arthritis in later life is unclear. 
The pathophysiology underlying HH-related arthritis has not been well studied and further 
research will be required to determine the iron and non-iron associated factors related to 
arthritis in HFE HH. 
While this study has analysed the phenotypic and clinical features of the four genetic forms of 
hepcidin-deficient HH there are some limitations. Firstly, this study relied on the collection of 
data from published studies, which did not have standard ways of reporting the data. 
Secondly the non-HFE HH group was limited to 156 subjects with adequate data derived from 
the global literature in comparison to 984 HFE HH subjects that were all derived from a single 
center. This difference likely reflects the rarity of non-HFE forms compared to the HFE form of 
HH.17 Thirdly, there was a significant amount of missing data, hence we analysed the data 
both with this missing data included and excluded. Finally, as the non-HFE HH data was 
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derived from published studies there may be some selection bias towards more severely 
affected cases. However, the same can be said for the comparator group of HFE HH 
subjects, which similar to most of the cases of non-HFE HH, were derived from referral to a 
center with research interests in the area of iron-related disorders. 
In conclusion, this analysis provides a reference framework that will be useful to clinicians for 
the differential diagnosis and management of patients with the various genetic forms of HH. A 
comprehensive international database for non-HFE HH of clinical and genetic variables will 
further assist in delineating and defining deficiencies related to iron loading in global 
populations allowing for more definitive clinical correlation. 
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Table 1: Genotypes of non-HFE HH subjects included in this study 
Gene Allele 1 Allele 2 N References 
HJV p.Leu28SerfsTer24 p.Leu28SerfsTer24 1 25 
HJV p.Arg54Ter p.Arg54Ter 1 26 
HJV p.Gly66Ter p.Gly66Ter 1 27 
HJV  p.Val74TrpfsTer40 p.Asn269LysfsTer43 2 15,28 
HJV p.Cys80Arg p.Leu101Pro 2 29 
HJV p.Cys80Tyr p.Gly320Val 1 30 
HJV p.Cys80Arg p.Arg326Ter 1 31 
HJV p.Ser85Pro p.Ser85Pro 1 28 
HJV p.Cys89Arg p.Cys89Arg 2 32 
HJV p.Gly99Arg p.Gly99Arg 3 30 
HJV p.Gly99Val p.Gly99Val 1 9,33 
HJV p.Gly99Arg  p.Leu101Pro 1 27 
HJV p.Leu101Pro p.Leu101Pro 4 29 
HJV p.Gln116Ter p.Gly320Val 1 34 
HJV p.Cys119Phe p.Cys119Phe 1 35 
HJV p.Arg131PhefsTer111 p.Arg131PhefsTer111 1 26 
HJV p.Asp149ThrfsTer97 p.Asp149ThrfsTer97 4 15,28 
HJV p.Leu165Ter p.Leu165Ter 1 36 
HJV  p.Ala168Asp p.Ala168Asp 1 28 
HJV p.Phe170Ser p.Phe170Ser 3 15,28 
HJV p.Asp172Glu p.Cys321ValfsTer21 1 28 
HJV p.Arg176Cys p.Arg176Cys 1 37 
HJV p.Arg176Cys p.Gly320Val 2 38,39 
HJV p.Trp191Cys p.Trp191Cys 1 28 
HJV p.Pro192Leu p.Pro192Leu 1 30 
HJV p.Leu194Pro p.Leu194Pro 1 30 
HJV p.Ser205Arg p.Gly250Val 2 15,28 
HJV p.Ile222Asn p.Gly320Val 4 9,15,29 
HJV p.Asp249His p.Asp249His 1 40 
HJV p.Ile281Thr p.Ile281Thr 1 9 
HJV p.Ile281Thr p.Cys321Ter 1 41 
HJV p.Arg288Trp p.Arg288Trp 3 28,42 
HJV p.Gln312Ter p.Gln312Ter 5 40,43 
HJV  p.Gly320Val p.Gly320Val 34 9,15,20,28,31,35,44-47  
HJV p.Gly320Val p.Cys321Trp 1 48 
HJV p.Gly320Val p.Arg326Ter 1 9 
HJV p.Gly320Val p.Ser328AspfsTer10 1 35 
HJV p.Ala343ProfsTer24 p.Ala343ProfsTer24 1 30 
HJV p.Cys361ValfsTer6 p.Cys361ValfsTer6 1 9 
HJV p.Arg385Ter p.Arg385Ter 3 15,28 
For personal use only.on June 10, 2018. by guest  www.bloodjournal.orgFrom 
28 
 
HAMP c.-25G>A c.-25G>A 3 49,50 
HAMP p.Gly32AspfsTer88 p.Gly32AspfsTer88 2 10,33 
HAMP p.Arg42SerfsTer78 p.Arg42SerfsTer78 1 30 
HAMP p.Arg56Ter p.Arg56Ter 1 10,15,21 
HAMP p.Cys70Arg p.Cys70Arg 1 51,52 
HAMP p.Arg75Ter p.Arg75Ter 1 53 
HAMP p.Cys78Tyr p.Cys78Tyr 2 54 
TFR2 p.Glu60Ter p.Glu60Ter 6 19 
TFR2 p.Glu60Ter p.Arg105Ter 1 55 
TFR2 p.Leu85_Ala96delinsPro p.Gly735Ser 1 56 
TFR2 p.Arg105Ter p.Arg105Ter 2 57 
TFR2 p.Met172Lys p.Met172Lys 4 19,58,59 
TFR2 c.614+4A>G c.614+4A>G 1 60 
TFR2 p.Tyr250Ter p.Tyr250Ter 8 11,61 
TFR2 p.Gln317Ter p.Gln317Ter 3 62 
TFR2 p.Arg396Ter c.1538-2A>G 1 63 
TFR2 p.Arg396Ter p.Gly792Arg 1 64 
TFR2 p.Asn411del p.Ala444Thr 1 65 
TFR2 p.Asn412Ile p.Asn412Ile 1 66 
TFR2 p.Gly430Arg p.Gly430Arg 1 66 
TFR2 p.Gly430Arg p.Tyr504Cys 1 67 
TFR2 p.Ala444Thr p.Gly792Arg 1 66 
TFR2 p.Leu490Arg p.Leu490Arg 1 68 
TFR2 p.Ser556AlafsTer6 p.Ser556AlafsTer6 1 68 
TFR2 p.Ala621_Gln624del p.Ala621_Gln624del 3 69 
TFR2 p.Arg679Pro p.Arg679Pro 1 66 
TFR2 p.Gln690Pro p.Gln690Pro 3 70 
TFR2 p.Met705HisfsTer87 p.Gly792Arg 1 66 
TFR2 c.2137-1G>A c.2137-1G>A 2 65 
TFR2 p.Arg730Cys p.Trp781Ter 1 66 
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Table 2. Logistic regression analyses of clinical features in HH subtypes compared to HFE probands 
  Odds ratios (95% CI) with HFE proband as the reference group 
Clinical Feature Model HJV/HAMP TFR2 HFE non-proband 
Cardiac Involvement 1 11.6 (6.4, 21.2) *** 4.9 (1.6, 14.6) ** 0.36 (0.15, 0.92) * 
 2 31.3 (10.1, 96.9) *** 7.1 (1.9, 26.7) ** 0.67 (0.25, 1.8)  
Hypogonadism 1 12.0 (7.2, 20.2) *** 3.9 (1.7, 9.0) ** 0.46 (0.29, 0.72) ** 
 2 19.4 (7.8, 48.2) *** 5.2 (1.8, 15.3) ** 1.1 (0.62, 1.8)  
Diabetes/hyperglycaemia 1 3.8 (2.1, 6.8) *** 2.4 (0.96, 6.2)  0.23 (0.12, 0.44) *** 
 2 8.4 (3.1, 23.1) *** 3.8 (1.2, 12.7) * 0.44 (0.22, 0.91) * 
Skin pigmentation 1 6.0 (3.3, 11.1) *** 1.8 (0.73, 4.4)  0.43 (0.30, 0.63) *** 
 2 12.4 (4.8, 32.2) *** 3.1 (0.93, 10.4)  1.1 (0.68, 1.70)  
Arthritis/arthropathy 1 0.47 (0.26, 0.86) * 0.85 (0.38, 1.9)  0.45 (0.33, 0.61) *** 
 2 1.2 (0.54, 2.6)  1.1 (0.40, 2.9)  0.77 (0.53, 1.1)  
Liver fibrosis/cirrhosis 1 3.4 (1.7, 6.5) *** 3.1 (1.0, 9.4) * 0.32 (0.22, 0.47) *** 
 2 3.0 (0.99, 8.8)  1.9 (0.47, 7.9)  0.55 (0.34, 0.88) * 
Logistic regression models were fit to examine how either the genetic form of HH (HFE, HJV/HAMP or TFR2) and in the case of 
HFE HH whether being a proband or non-proband is associated with a clinical feature using 2 models: (1) not adjusting for any 
variables, (2) adjusting for age group (<25y,25-34y, 35-44y, 45-54y, 55y+), sex and log SF. In this analysis subjects with 
missing data for a particular clinical feature were excluded. Statistically significant differences are denoted as *** p<0.001, ** 
p<0.01, * p<0.05. For personal use only.
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Figure 1. Age at diagnosis of subjects with non-HFE and HFE-related HH. 
The age at diagnosis is shown for subjects with HJV, HAMP, TFR2 and HFE-related HH. 
Subjects with HFE HH have been divided into probands and non-probands. Graphs show 
individual data points and box and whisker plots show median value, upper and lower 
quartiles and range. Variables were compared using 1- way-ANOVA and Tukey’s multiple 
comparison test. Statistically significant differences are denoted as (a) compared to HJV, (b) 
compared to HAMP, (c) compared to TFR2, and (d) compared to HFE proband. 
Figure 2. Serum iron indices at diagnosis. 
(A) Serum ferritin (μg/L) and (B) transferrin saturation (%) at diagnosis is shown for subjects 
with HJV, HAMP, TFR2 and HFE related HH. Subjects with HFE HH have been divided into 
probands and non-probands. Graphs show individual data points and box and whisker plots 
show the median value, upper and lower quartiles and range. Variables were compared 
using the Kruskal-Wallis and Dunn’s multiple comparison tests. Statistically significant 
differences are denoted as (a) compared to HJV, (b) compared to HAMP, (c) compared to 
TFR2, and (d) compared to HFE proband. 
Figure 3. Clinical features of subjects with non-HFE and HFE-related HH. 
The presence or absence of clinical features was determined in all subjects with a genetic 
diagnosis of HJV, HAMP, TFR2 or HFE related HH. Subjects with HFE HH have been divided 
into probands and non-probands. Differences in the prevalence of clinical features between 
the HFE (proband) group and all other groups were compared using Fisher’s exact test. 
Statistically significant differences are denoted as **** p<0.0001, *** p<0.001, ** p<0.01, 
*p<0.05. For statistical analyses in (F) liver fibrosis and cirrhosis were combined. For the 
statistical analyses denoted by asterisks above the boxes, subjects with missing data for a 
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particular clinical feature were assumed to not have that clinical feature. For the statistical 
analyses denoted by asterisks inside the boxes, subjects with missing data were excluded. 
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